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The effect of occlusive portal vein thrombosis (PVT) on the mortality of pediatric liver transplant candidates and recipients
is poorly defined. Using standard multivariate techniques, we studied the relationship between PVT and waiting-list and
posttransplant survival rates with data from the Scientific Registry of Transplant Recipients (September 2001 to December
2007). In all, 5087 liver transplant candidates and 3630 liver transplant recipients were evaluated during the period. PVT
was found in 1.4% of the liver transplant candidates (n ¼ 70) and in 3.7% of the liver transplant recipients (n ¼ 136). PVT
was not associated with increased wait-list mortality [hazard ratio (HR) ¼ 1.1, 95% confidence interval (CI) ¼ 0.5-2.4, P ¼
0.77]. Conversely, PVT patients had a significantly lower unadjusted survival rate in the posttransplant period (P ¼ 0.01).
PVT was independently associated with increased posttransplant mortality in multivariate models (30-day survival: HR ¼
2.9, 95% CI ¼ 1.6-5.3, P ¼ 0.001; overall survival: HR ¼ 1.7, 95% CI ¼ 1.1-2.4, P ¼ 0.01). The presence of PVT in pediat-
ric liver candidates was not associated with increased wait-list mortality but was clearly associated with posttransplant mor-
tality, especially in the immediate postoperative period. Liver Transpl 17:1066-1072, 2011. VC 2011 AASLD.
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Portal vein thrombosis (PVT) is a common sequela of
chronic liver disease in both adult and pediatric
patients.1-4 Architectural changes in the liver paren-
chyma secondary to chronic liver disease increase the
resistance to the portal vein blood flow and result in
venous stasis. A patient’s susceptibility to thrombo-
genesis is increased by acquired or inherited hyper-
coagulopathies.2,5,6 Although patients with PVT may
present with acute hepatic decompensation, it is more
often diagnosed as an incidental finding during the
pretransplant radiographic evaluation or during liver
transplantation.1,7 Occlusive PVT leads to severe por-
tal hypertension and significant morbidity related to
ascites, hepatohydrothorax, hypersplenism, or vari-
ceal bleeding. Improvements in the prophylactic man-
agement of esophageal varices have reduced the risk
of bleeding, but these cirrhosis-related complications
are particularly difficult to manage in children.3,5,8-11
Despite these complications, the natural history of
PVT in children is poorly described and is not well
understood. The current literature consists primarily
of single-center reports, and the reported incidence of
PVT has varied widely (as high as 10% in candidates
and 16% in recipients).12,13 Our previous work sug-
gests that PVT is associated with increased mortality
in adult liver transplant recipients, but the outcomes
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remain less clear for pediatric liver transplant candi-
dates.14,15 It is critical for us to understand the com-
plex relationship between PVT and survival in both
the waiting-list and post–liver transplant pediatric
populations. This knowledge could help us to optimize
the timing of liver transplantation for children at risk
for devastating complications. In short, large multi-
center studies or clinical registry data are needed to
best understand and care for these complex patients.
Within this context, we studied PVT in pediatric
liver transplant candidates and recipients with a
national sample derived from data from the Scientific
Registry of Transplant Recipients (SRTR). We hypothe-
sized that pediatric patients with PVT would have an
increased risk of mortality both on the waiting list
and after liver transplantation. In this case, trans-
plant pediatricians might want to consider policies
that facilitate early transplantation for these complex
patients even while they are still considering the
implications of PVT for posttransplant survival.
PATIENTS AND METHODS
Study Population
This study was approved by the University of Michi-
gan Institutional Review Board.
SRTR data were obtained and were based on
patient-level data submitted by transplant centers in
the United States to the Organ Procurement and
Transplantation Network. All liver transplant candi-
dates who were initially wait-listed at an age < 18
years between September 2001 and December 2007
were included in the study cohort.
In the SRTR database, the PVT status is reported at
2 different times: the time of listing (ie, for liver trans-
plant candidates) and the time of transplantation (ie,
for transplant recipients). As in our previous
works,13,14,16 the PVT field from the candidate file
was used for the purpose of evaluating wait-list mor-
tality. For the analysis involving transplant recipients,
the PVT field from the recipient file was used. As pre-
viously noted, the PVT fields in the candidate and re-
cipient files frequently did not match. For example,
PVT was noted in 70 liver transplant candidates and
in 136 liver transplant recipients. This likely occurred
for 2 reasons. First, PVT is frequently diagnosed at
the time of liver transplantation. Second, even if PVT
is diagnosed before transplantation, the data recorded
in the candidate history files are rarely updated by
transplant centers, except for variables that would
change the Model for End-Stage Liver Disease (MELD)
or Pediatric End-Stage Liver Disease (PELD) score. If
our goal is to make clinical policy recommendations,
using data from the recipient files for wait-list out-
come measurements would not be clinically valid;
therefore, we did not specifically make adjustments
when the 2 PVT covariates were not in agreement.
Each candidate was observed until death, and cen-
soring was performed only for the earliest of the fol-
lowing: living donor liver transplantation, the candi-
date’s loss to follow-up, or the end of the observation
period (December 31, 2007). If a candidate was removed
from the wait list, he was assumed to have died.
PVT in Liver Transplant Candidates
For the purpose of descriptive analysis, the study
cohort of candidates was divided into 2 groups: liver
transplant candidates with PVT (PVT candidates) and
liver transplant candidates without PVT (non-PVT
candidates). For all candidates, univariate compari-
sons were made between the PVT and non-PVT
groups. Kaplan-Meier survival curves were created to
compare the survival rates of the liver transplant can-
didates with and without PVT, and the log-rank test
was used for statistical comparisons. For the longer
term follow-up of candidates with PVT, we did not
have an adequate sample size to support a valid
model, so time points after this threshold are not dis-
played on the Kaplan-Meier curve. A Cox regression
was used to estimate the covariate-adjusted effect of
PVT on wait-list mortality. Each candidate was
observed until death, and censoring was performed
only for the earliest of the following: living or deceased
donor liver transplantation, the candidate’s loss to fol-
low-up, or the end of the observation period (Decem-
ber 31, 2007). Each model included an indicator for
the PVT status [(1) yes or (0) no] and the following
adjustment covariates: race, sex, age, dialysis status,
bilirubin, international normalized ratio (INR), albu-
min, sodium, and a history of malignancy. No covari-
ates were time-dependent, and the inactive time was
included in the analysis.
For the Cox time-to-transplant model, patients
began their follow-up on the date of their initial place-
ment on the waiting list, and they were followed until
the earliest of the following: death, living or deceased
donor liver transplantation, their loss to follow-up, or
the end of the study. The model adjustment covariates
included the following: race, sex, age, dialysis status,
bilirubin, INR, albumin, sodium, and a history of hep-
atoblastoma. No covariates were time-dependent, and
the inactive time was included in the analysis.
PVT in Deceased Donor Liver
Transplant Recipients
For all recipients, univariate comparisons were made
between the PVT and non-PVT groups. Kaplan-Meier
survival curves were created to compare the survival
rates of the liver transplant recipients with and with-
out PVT, and the log-rank test was used for statistical
comparisons. For the longer term follow-up of recipi-
ents with PVT, we did not have an adequate sample
size to support a valid model, so time points after this
threshold are not displayed on the Kaplan-Meier curve.
For the posttransplant mortality model, recipients
began their follow-up at the time of liver transplanta-
tion (deceased or living). For the model of 30-day sur-
vival, the patients were followed until death or the
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end of the observation time (30 days after transplan-
tation). For the model of overall survival, the patients
were followed until death or their loss to follow-up
(<1% of recipients). No covariates were time-depend-
ent. The final pretransplant values were coded for cre-
atinine, bilirubin, albumin, INR, sodium, and dialysis.
In addition to the aforementioned covariates, the post-
transplant mortality models also included the follow-
ing recipient characteristics at the time of transplan-
tation: sex, age, liver disease etiology, living donor
status, and donor risk index components (ie, the
donor’s age, race, and cause of death, the donation af-
ter cardiac death status, and the split liver status).
All statistical analyses were performed with SAS
9.3.1 (SAS Institute, Cary, NC).
RESULTS
PVT in Liver Transplant Candidates
The characteristics of the pediatric candidates with
and without PVT who were wait-listed for liver trans-
plantation are displayed in Table 1. The prevalence of
PVT (reported in the national database) among the
5087 candidates was 1.4% (n ¼ 70). Candidates with
PVT were more likely to be female (70.0% versus
51.0%, P ¼ 0.002) and to have a lower PELD/MELD
score when they were placed on the transplant list
(9.9 6 13.2 versus 15.3 6 13.7, P ¼ 0.001). The fol-
lowing factors did not differ significantly between PVT
and non-PVT candidates: age, race, body mass index,
dialysis status, and previous transplant status. A di-
agnosis of biliary atresia was not more common
among candidates with PVT, and the survival of bili-
ary atresia candidates was not significantly different
from the survival of candidates without biliary atresia
(P ¼ 0.72).
Kaplan-Meier survival curves were created to com-
pare the survival rates of liver transplant candidates
with and without PVT (Fig. 1). The unadjusted sur-
vival rate was not significantly lower for liver trans-
plant candidates with PVT (P ¼ 0.797).
We first assessed the relationship between PVT and
wait-list mortality with a univariate Cox regression
model. PVT was not significantly associated with wait-
list mortality [hazard ratio (HR) ¼ 1.1, 95% confidence
interval (CI) ¼ 0.5-2.4, P ¼ 0.77]. In an attempt to elu-
cidate the characteristics independently associated
with wait-list mortality for all the candidates, we
performed a multivariate Cox regression analysis,
which is presented in Fig. 2. Once again, PVT was not
significantly associated with wait-list mortality by
TABLE 1. Characteristics of Pediatric Liver Transplant Candidates With or Without PVT (n 5 5087)
Characteristic Candidates Without PVT (n ¼ 5017) Candidates With PVT (n ¼ 70) P Value
Age (years)* 5 6 6.0 6 6 6.3 0.103
Race [n (%)] 0.64
Caucasian 2593 (51.7) 37 (52.9)
African American 860 (17.1) 10 (14.3)
Asian 256 (5.1) 2 (2.9)
Hispanic 1166 (23.2) 19 (27.1)
Other 142 (2.8) 2 (2.9)
Sex, female [n (%)] 2559 (51.0) 49 (70.0) 0.002
PELD score at listing* 15.3 6 13.7 9.9 6 13.2 0.001
Body mass index (kg/m2)* 18.1 6 4.5 18.6 6 4.1 0.35
Dialysis [n (%)] 137 (2.7) 1 (1.4) >0.99
Previous liver transplant [n (%)] 535 (10.7) 12 (17.1) 0.082
*The data are presented as means and standard deviations.
Figure 1. Kaplan-Meier survival curves for wait-listed liver
transplant candidates with or without PVT.
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multivariate analysis (HR ¼ 1.4, 95% CI ¼ 0.7-3.0, P
¼ 0.38). Female sex was associated with a signifi-
cantly decreased covariate-adjusted mortality risk (HR
¼ 0.8, 95% CI ¼ 0.6-0.9, P ¼ 0.003), whereas candi-
dates who were 2 years of age or younger had an
increased mortality risk (HR ¼ 2.6, 95% CI ¼ 1.9-3.4,
P < 0.001) in comparison with candidates between
the ages of 3 and 11 years. In addition, both bilirubin
and INR values were associated with wait-list
mortality.
We then investigated the relationship between the
reported PVT status and the transplant rate. A covari-
ate-adjusted Cox regression was performed in an
effort to determine the candidate characteristics inde-
pendently associated with the liver transplant rate.
PVT was not independently associated with the
adjusted liver transplant rate (HR ¼ 0.9, 95% CI ¼
0.8-1.1, P ¼ 0.35). However, candidates were more
likely to receive a transplant if they were female (HR ¼
1.1, 95% CI ¼ 1.0-1.1, P ¼ 0.001), 2 years old or
younger (HR ¼ 1.1, 95% CI ¼ 1.0-1.1, P < 0.001), or
12 to 18 years old (HR ¼ 1.4, 95% CI ¼ 1.3-1.5, P <
0.001; the age reference group consisted of candidates
who were 3 to 11 years old). Similarly, candidates
with a blood sodium level between 132 and 137 mEq/
L had an increased rate of transplantation (HR ¼ 1.2,
95% CI ¼ 1.1-1.2, P < 0.001), whereas a mean so-
dium level less than 132 mEq/L was not significantly
correlated. As expected, the following PELD/MELD
components were significantly associated with the
transplant rate: INR (HR ¼ 1.13, 95% CI ¼ 1.06-1.20,
P < 0.001), bilirubin (HR ¼ 1.25, 95% CI ¼ 1.23-1.28,
P < 0.001), albumin (HR ¼ 0.63, 95% CI ¼ 0.59-0.67,
P < 0.001), and dialysis (HR ¼ 1.4, 95% CI ¼ 1.2-1.6,
P < 0.001). Race and a previous diagnosis of malig-
nancy were not associated with the transplantation
rate.
PVT in Liver Transplant Recipients
The characteristics of pediatric liver transplant recipi-
ents with and without PVT and their donors are dis-
played in Table 2. In all, 3630 patients received a liver
transplant, and 3.7% of these patients (n ¼ 136) were
reported to have PVT. The graft donor characteristics,
such as the donor age, the donor weight, and the do-
nor risk index, were not significantly different between
the groups. In addition, the utilization of deceased do-
nor split liver grafts and living donor grafts was simi-
lar between the 2 groups. PVT recipients were more
likely to be female (64.7% versus 51.1%, P ¼ 0.002).
The following recipient characteristics did not differ
significantly between the groups: age, race, PELD
score at transplant, albumin, sodium, and ascites.
PVT was not associated with a diagnosis of biliary
atresia, although this assessment was limited by the
small sample size. More specifically, 1496 recipients
were listed with biliary atresia as the primary diagno-
sis. Forty of these recipients had PVT, and there were
4 deaths.
Kaplan-Meier survival curves were created to com-
pare the survival rates of the liver transplant recipi-
ents with and without PVT (Fig. 3). The unadjusted
survival rate was significantly lower in the PVT group
across the posttransplant period (P ¼ 0.01). The sur-
vival rate was particularly lower in the first few
months after transplantation and then continued to
trend downward like that of the non-PVT recipients.
We then assessed the implications of PVT for short-
term posttransplant survival (30-day survival). PVT
was significantly associated with 30-day mortality (HR
¼ 2.9, 95% CI ¼ 1.6-5.3, P ¼ 0.001). Other covariates
that were significantly associated with short-term
mortality included the following: creatinine (HR ¼
4.42, 95% CI ¼ 2.8-7.1, P ¼ 0.001), INR (HR ¼ 1.6,
95% CI ¼ 1.1-2.4, P ¼ 0.02), a recipient age of 0 to 2
years versus a recipient age of 3 to 11 years (HR ¼
1.7, 95% CI ¼ 1.1-2.6, P ¼ 0.014), and donor age (HR
¼ 1.02, 95% CI ¼ 1.01-1.04, P ¼ 0.01). No statistical
interactions between PVT and the other covariates
(including the age at transplantation) were noted.
A univariate regression was performed to determine
the effects of PVT on overall posttransplant mortality.
Recipients with PVT showed increased posttransplant
mortality (HR ¼ 1.7, 95% CI ¼ 1.2-2.5, P ¼ 0.007).
These results were corroborated by a multivariate Cox
regression analysis, which revealed that PVT was sig-
nificantly associated with adjusted posttransplant
mortality (HR ¼ 1.6, 95% CI ¼ 1.0-2.4, P ¼ 0.03), as
displayed in Fig. 4. The model was adjusted for sex,
Figure 2. Multivariate Cox regression analysis of wait-list
mortality in pediatric liver transplant candidates. PVT was not
significantly correlated with the wait-list mortality risk. Female
candidates had a decreased mortality risk (HR ¼ 0.8, 95% CI ¼
0.6-0.9, P ¼ 0.003), and candidates who were 0 to 2 years old
had an increased risk (HR ¼ 2.6, 95% CI ¼ 1.9-3.4, P < 0.001).
LIVER TRANSPLANTATION, Vol. 17, No. 9, 2011 WAITS ET AL. 1069




PVT (n ¼ 3494)
Recipients
With
PVT (n ¼ 136) P Value
Donor
Age (years)* 15 6 14.7 13 6 14.1 0.19
Weight (kg)* 42.1 6 28.8 38.8 6 28.8 0.19
Graft type [n (%)]
Deceased donor whole 2135 (61.1) 89 (65.4) 0.31
Deceased donor split 922 (26.4) 36 (26.5) 0.98
Living donor 437 (12.5) 11 (8.1) 0.12
Donor risk index* 2.0 6 0.6 2.0 6 0.6 0.58
Cold time (hours)* 7.3 6 4.0 7.4 6 2.8 0.56
Recipient
Age (years)* 5 6 5.8 4 6 6.0 0.53
Race [n (%)] 0.35
Caucasian 1825 (52.2) 79 (58.1)
African American 609 (17.4) 17 (12.5)
Asian 188 (5.4) 4 (2.9)
Hispanic 776 (22.2) 30 (22.1)
Other 96 (2.7) 6 (4.4)
Sex, female [n (%)] 1784 (51.1) 88 (64.7) 0.002
PELD score at transplant* 15.7 6 13.8 14.2 6 12.3 0.21
Albumin (g/dL)* 3.1 6 0.8 3.0 6 0.8 0.31
Sodium (mEq/L)* 137.9 6 5.4 137.8 6 7.1 0.87
Ascites [n (%)] 1436 (41.1) 64 (47.1) 0.17
*The data are presented as means and standard deviations.
Figure 3. Kaplan-Meier survival curves for liver transplant
recipients with or without PVT.
Figure 4. Multivariate Cox regression analysis of posttransplant
mortality in pediatric liver transplant recipients. Pediatric liver
transplant recipients with PVT had a significantly increased risk
of mortality in comparison with recipients without PVT (HR ¼
1.661, 95% CI ¼ 1.131-2.441, P ¼ 0.01). No other factor was
significantly associated with the risk of mortality.
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age, race, creatinine, bilirubin, INR, albumin, sodium,
dialysis status, graft type, retransplantation status,
and a previous diagnosis of malignancy.
DISCUSSION
In this work, we have investigated the relationship
between PVT and survival for pediatric liver trans-
plant candidates and recipients. Our hypothesis was
that liver transplant candidates and recipients with
PVT would have a significantly higher risk of mortal-
ity. In fact, we noted a significantly higher rate of
posttransplant mortality only in the liver transplant
recipients with PVT (3.6%); we did not note a statisti-
cally significant relationship between PVT and wait-
list mortality. Although this study has several impor-
tant limitations, it is the largest known study of PVT
and pediatric liver transplantation. In this context,
these analyses do not specifically support policies
facilitating early transplantation for pediatric patients
with PVT. This conclusion should be considered
within the context of the limitations of this registry-
based analysis.
PVT is likely due to a combination of decreased por-
tal venous blood flow (related to cirrhosis, mesenteric
venous hypoplasia, or both) and hypercoagulability
(eg, acquired protein C and S deficiencies). PVT
increases the postoperative risk of death after adult
liver transplantation.14,17 This study shows similar
posttransplant survival outcomes and agrees with
previous studies of pediatric liver transplant
patients.13 The implications of PVT for the survival of
children on the wait list remain less clear. Although
we noted a trend toward inferior survival, this trend
was not statistically significant. Previous studies of
adult liver transplant populations have noted similar
findings.14,16
When the results of our study are being considered,
it is important to understand the limitations of retro-
spective observational data. The most important limi-
tation of this study is that our ability to truly define
the incidence of PVT in the pediatric population with
liver diseases is restricted. Only 3.7% of the children
who underwent liver transplantation had PVT in our
study. Smaller, single-center studies (by our group)
have demonstrated much higher rates of PVT in
transplant recipients (10%), and this may demon-
strate underdetection within the national registry
data.13 A prospective screening study with a large
number of centers would be needed for an accurate
determination of the incidence of PVT. Another impor-
tant limitation involves the characterization of PVT
(complete or partial). In previous work,13,16 we
assigned a specific definition to PVT so that only
cases of occlusive thrombosis of the main portal vein
were included. This rigorous definition of PVT is not
possible with Organ Procurement and Transplanta-
tion Network data; as a result, we are not able to con-
firm the reliability of the PVT data reported by trans-
plant centers. Clearly, the management of complete
PVT is significantly more complex at the time of trans-
plantation. Another limitation involves the lack of
data on patients with end-stage liver disease who
were never listed for transplantation. Future studies
may seek to include these patients because they likely
represent a particularly sick cohort of patients.
Finally, there are likely associations between biliary
atresia and PVT that are not able to be fully under-
stood because of the limitations of this data set. More
specifically, pediatric patients with biliary atresia may
present with a complex mesenteric venous anatomy.
Clearly, the complexity of their clinical scenario is not
adequately represented by national registry data. Fur-
thermore, this analysis is limited by the small sample
size and event rates for biliary atresia patients with
PVT (only 40 recipients and 4 deaths). Additional
studies using more robust data sources are needed to
better understand the relationships between biliary
atresia, PVT and anatomic variations, and outcomes.
Our data suggest that much of the increased risk of
postoperative mortality is directly related to the trans-
plant operation. Certainly, there are several options
for the surgical management of this complex problem,
and it is critical that the mesenteric vascular anatomy
be fully understood before transplantation. Because
mesenteric venous hypoplasia is common in the set-
ting of biliary atresia, a complete preoperative radio-
graphic workup is particularly important for these
patients. Recent studies comparing preoperative
assessments of the hepatic and portal vasculature
have shown that Doppler ultrasound can be a useful
initial screening test and should be followed by com-
puted tomography venography or magnetic resonance
venography for definitive operative planning.18,19
These studies can also help us to recognize important
vascular anomalies such as a preduodenal portal vein
or the absence of a portal vein.
In summary, PVT is associated with an increase in
the postoperative mortality rate, although the rela-
tionship between PVT and wait-list mortality remains
less clear. Additional work is needed to understand
the incidence of this disease, and there should be a
particular focus on children who may have PVT but
are never listed for transplantation. Although further
investigations are needed to delineate the best options
for the management of PVT in liver transplant recipi-
ents, a careful preoperative diagnosis and planning
offer the best opportunities for improvements in post-
operative survival outcomes. Finally, although some
limitations exist, this work does not seem to support
broad-based policy efforts that would facilitate early
transplantation for pediatric patients with PVT.
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